Cytek Biosciences, Inc. (CTKB) Key Metrics
CTKB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $682.4M
- Enterprise value
- $502.8M
- P/E (TTM)
- —
- Forward P/E
- 370.4
- PEG ratio
- —
- Price / sales
- 3.3 10-yr median 6.4
- Price / book
- 2.3 10-yr median 3.1
- EV / EBITDA
- 222.7 10-yr median 122.5
- Dividend yield
- —
- Beta
- 1.16
CTKB key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCTKB valuation Price multiples at each fiscal year-end price.
CTKB returns How much profit the business earns on the capital it uses.
CTKB per-share figures Results divided by the shares outstanding at year-end.
CTKB financial health Debt, liquidity and how easily interest is covered.
CTKB efficiency & capital use Working capital cycle and where the cash goes.
CTKB valuation history
CTKB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CTKB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CTKB cash returned to shareholders
CTKB price vs earnings per share
CTKB key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $645.1M | $847.7M | $1.23B | $1.41B | $2.18B | — | — |
| Enterprise value | $407.3M | $586.8M | $985.5M | $1.09B | $1.83B | — | — |
| P/E ratio | — | — | — | 549.2 | 727.4 | — | — |
| Price / sales | 3.2 | 4.2 | 6.4 | 8.6 | 17.1 | — | — |
| Price / book | 1.9 | 2.1 | 3.1 | 3.3 | 5.4 | — | — |
| Price / free cash flow | — | 38.8 | — | — | — | — | — |
| Price / operating cash flow | — | 33.4 | 233.6 | — | 471.4 | — | — |
| EV / sales | 2.0 | 2.9 | 5.1 | 6.7 | 14.3 | — | — |
| EV / EBITDA | — | 122.5 | — | 115.0 | 205.5 | — | — |
| EV / free cash flow | — | 26.9 | — | — | — | — | — |
| Earnings yield | −10.3% | −0.7% | −1.0% | 0.2% | 0.1% | — | — |
| Free cash flow yield | −1.4% | 2.6% | 0.0% | −1.6% | 0.0% | — | — |
| Dividend yield | — | — | 0.1% | 0.0% | — | — | — |
| Shareholder yield (dividends + buybacks) | 2.3% | 2.5% | 3.7% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $5.05 | $6.49 | $9.12 | $10.21 | $16.32 | — | — |
| Per share | |||||||
| Revenue per share | $1.58 | $1.53 | $1.43 | $1.18 | $0.96 | $0.70 | $0.44 |
| Earnings per share | −$0.52 | −$0.05 | −$0.09 | $0.02 | $0.02 | $0.15 | −$0.13 |
| Operating cash flow per share | −$0.04 | $0.19 | $0.04 | −$0.09 | $0.03 | $0.11 | −$0.10 |
| Free cash flow per share | −$0.07 | $0.17 | $0.00 | −$0.16 | $0.00 | $0.10 | −$0.11 |
| Cash per share | $2.05 | $2.13 | $1.94 | $2.46 | $2.73 | $1.24 | $0.23 |
| Book value per share | $2.68 | $3.03 | $2.91 | $3.07 | $3.03 | −$0.12 | −$0.31 |
| Tangible book value per share | $2.41 | $2.75 | $2.62 | $2.96 | $2.92 | −$0.13 | −$0.32 |
| Dividends per share | — | — | $0.01 | $0.00 | — | — | — |
| Capex per share | $0.03 | $0.03 | $0.04 | $0.07 | $0.03 | $0.01 | $0.01 |
| Debt per share | $0.19 | $0.13 | $0.10 | $0.13 | $0.11 | $0.02 | $0.05 |
| Shares outstanding | 127.7M | 130.6M | 135.3M | 138.6M | 133.7M | 133.0M | 133.0M |
| Change in shares outstanding | −2.2% | −3.5% | −2.4% | +3.6% | +0.6% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −18.0% | −1.5% | −3.0% | 0.6% | 1.5% | — | — |
| Return on invested capital (ROIC) | −26.7% | −11.6% | −17.8% | −2.3% | — | — | — |
| Return on assets (ROA) | −13.8% | −1.2% | −2.4% | 0.5% | 0.9% | 13.4% | −23.9% |
| Return on tangible assets | −15.5% | −1.3% | −2.7% | 0.5% | 0.7% | 8.9% | −24.2% |
| Free cash flow margin | −4.4% | 10.9% | 0.2% | −13.5% | 0.2% | 14.7% | −25.4% |
| Income quality (OCF / net income) | — | — | — | −4.75 | 1.54 | 0.78 | — |
| Financial health | |||||||
| Total debt | $23.7M | $17.0M | $14.1M | $18.1M | $15.3M | $2.8M | $7.2M |
| Cash & short-term investments | $261.5M | $277.9M | $262.4M | $341.1M | $364.6M | $165.2M | $30.1M |
| Net debt | −$237.8M | −$260.8M | −$248.3M | −$323.1M | −$349.4M | −$162.5M | −$22.9M |
| Debt / equity | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | — | — |
| Debt / assets | 0.05 | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | 0.10 |
| Net debt / EBITDA | — | −54.46 | — | −34.03 | −39.16 | −10.57 | — |
| Current ratio | 5.04 | 5.86 | 6.97 | 9.26 | 13.01 | 7.86 | 3.22 |
| Quick ratio | 4.42 | 5.21 | 5.89 | 8.28 | 12.04 | 6.99 | 2.34 |
| Interest coverage | -85.2 | -3.9 | -13.4 | -0.7 | 5.3 | 41.0 | — |
| Working capital | $314.2M | $328.8M | $335.8M | $405.0M | $398.6M | $182.1M | $46.7M |
| Invested capital | $104.0M | $134.9M | $144.8M | $102.2M | $55.7M | −$178.5M | −$64.6M |
| Tangible asset value | $308.2M | $358.9M | $353.8M | $411.1M | $390.5M | −$16.8M | −$42.4M |
| Net current asset value | $272.2M | $292.7M | $290.7M | $360.1M | $373.8M | −$27.4M | −$44.3M |
| Graham number | — | — | — | $1.13 | $1.24 | — | — |
| Graham net-net per share | $1.72 | $1.85 | $1.73 | $2.23 | $2.58 | −$0.34 | −$0.45 |
| Capital allocation | |||||||
| Dividends paid | — | — | $1.5M | $209,000 | — | — | — |
| Share buybacks (net) | $15.1M | $21.6M | $44.2M | $209,000 | $0 | — | — |
| Dividend payout ratio | — | — | — | 8.1% | — | — | — |
| Dividends + buybacks / free cash flow | — | 98.9% | — | — | 0.0% | — | — |
| Capex / revenue | 2.0% | 1.8% | 2.5% | 6.0% | 3.4% | 1.7% | 1.7% |
| Capex / operating cash flow | — | 13.9% | 91.4% | — | 94.3% | 10.2% | — |
| Capex / depreciation | 0.34 | 0.34 | 0.52 | 1.74 | 3.51 | 2.57 | 3.15 |
| Stock-based compensation / revenue | 12.2% | 13.4% | 11.4% | 10.1% | 5.1% | 0.7% | 0.5% |
| R&D / revenue | 18.1% | 19.7% | 22.9% | 21.3% | 19.1% | 14.7% | 15.4% |
| SG&A / revenue | 53.8% | 46.0% | 48.2% | 41.4% | 35.6% | 26.2% | 29.3% |
| Efficiency | |||||||
| Days sales outstanding | 120.2 | 106.3 | 101.2 | 89.6 | 68.1 | 70.5 | 111.9 |
| Days of inventory on hand | 173.6 | 214.0 | 238.0 | 232.5 | 206.4 | 183.9 | 230.4 |
| Days payables outstanding | 22.5 | 17.5 | 17.1 | 22.7 | 22.4 | 23.5 | 29.3 |
| Cash conversion cycle (days) | 271.4 | 302.8 | 322.1 | 299.3 | 252.1 | 231.0 | 313.0 |
| Receivables turnover | 3.04 | 3.44 | 3.61 | 4.08 | 5.36 | 5.18 | 3.26 |
| Payables turnover | 16.25 | 20.87 | 21.33 | 16.09 | 16.33 | 15.56 | 12.47 |
| Inventory turnover | 2.10 | 1.71 | 1.53 | 1.57 | 1.77 | 1.98 | 1.58 |
| Asset turnover | 0.42 | 0.40 | 0.38 | 0.33 | 0.37 | 0.64 | 0.82 |
| Average receivables | $66.4M | $58.4M | $53.5M | $40.3M | $23.9M | $17.9M | $17.7M |
| Average payables | $6.0M | $4.3M | $3.9M | $3.9M | $3.0M | $2.6M | $2.3M |
| Average inventory | $46.2M | $52.4M | $54.5M | $40.2M | $27.6M | $20.7M | $18.4M |
| Intangibles / total assets | 7.3% | 7.4% | 7.9% | 2.8% | 3.2% | 0.3% | 1.1% |
Computed from CTKB's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CTKB valuation and financial ratios
Cytek Biosciences earned a return on equity of −18.0% and a return on invested capital of −26.7% in fiscal 2025. It ended the year with $23.7 million of debt and $261.5 million in cash and short-term investments, a net cash position of $237.8 million. It returned $15.1 million to shareholders: $0 in dividends and $15.1 million in share buybacks. The share count fell 3.9% from 133.0M to 127.7M over 6 years.
See the CTKB income statement, the CTKB chart for price history, or the CTKB stock overview for the latest quote and news.
CTKB key metrics FAQ
What is Cytek Biosciences's return on equity?
Cytek Biosciences's return on equity (ROE) was −18.0% in fiscal 2025: net income of -$66.5 million on average shareholders' equity of $368.7 million.
What is Cytek Biosciences's ROIC?
Cytek Biosciences's return on invested capital was −26.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Cytek Biosciences have?
Cytek Biosciences had total debt of $23.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.07 and more cash than debt.
Does Cytek Biosciences buy back its shares?
Yes. Cytek Biosciences spent $15.1 million on net share repurchases in fiscal 2025 Shares outstanding changed −2.2% over the year, to 127.7M..
What is Cytek Biosciences's free cash flow yield?
Cytek Biosciences generated -$8.8 million of free cash flow in fiscal 2025, a free cash flow yield of −1.4% on its market value at year-end ($645.1 million).
What is Cytek Biosciences's current ratio?
Cytek Biosciences's current ratio was 5.04 at the end of fiscal 2025: current assets were 5.04 times current liabilities.